GlassScriptPhysician profile
Darrin Coulter
NPI 1932683802
$3,939.92
in general payments reported to CMS, 2019-2025
27 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.07 · 2022: $800 · 2023: $462 · 2024: $1,280 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,082.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $529.85 | 2022-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $415.46 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $364.64 | 2022-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $269.67 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $267.68 | 2022-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.84 | 2022-2025 | Caplyta |
| Tris Pharma INC | $186.73 | 2022-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $183.75 | 2022-2025 | Adzenys Xr-Odt |
| Alkermes, INC. | $174.36 | 2023-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $156.55 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $156.36 | 2025 | Cobenfy |
| Almatica Pharma LLC | $135.31 | 2023-2025 | Loreev Xr |
| Bausch Health US, LLC | $108.13 | 2023-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $102.19 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $99.49 | 2024-2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $82.59 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $80.25 | 2022-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $78.59 | 2022-2025 | |
| Indivior INC. | $59.22 | 2024-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $53.09 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $40.14 | 2025 | Relexxii |
| Horizon Therapeutics Plc | $32.99 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.31 | 2023-2024 | Quviviq |
| Luye Pharma (USA) LTD. | $29.50 | 2025 | Erzofri Extended-Release |
| Genentech USA, INC. | $24.08 | 2021 | |
| Noven Therapeutics, LLC | $22.92 | 2024 | Xelstrym |
| Jazz Pharmaceuticals INC. | $17.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrin Coulter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.